Eisai Inc. drugs
6 results
Banzel (rufinamide)
(rufinamide)Eisai Inc.
Usage: BANZEL is indicated as an adjunct treatment for seizures associated with Lennox-Gastaut Syndrome in pediatric patients aged 1 year and older, as well as in adults.
Dayvigo (lemborexant)
(lemborexant)Eisai Inc.
Usage: DAYVIGO is indicated for treating insomnia in adult patients, specifically for those experiencing difficulties with sleep onset and/or sleep maintenance.
Fycompa (perampanel)
(perampanel)Eisai Inc.
Usage: FYCOMPA is indicated for the treatment of partial-onset seizures in patients aged 4 years and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 12 years and older with epilepsy.
Halaven (eribulin mesylate)
(eribulin mesylate)Eisai Inc.
Usage: HALAVEN is indicated for patients with metastatic breast cancer who have received at least two prior chemotherapy regimens, including an anthracycline and a taxane. It is also used for unresectable or metastatic liposarcoma after a prior anthracycline-containing regimen.
Lenvima (lenvatinib)
(Lenvatinib)Eisai Inc.
Usage: LENVIMA is indicated for adult patients with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (both as first-line and following prior anti-angiogenic therapy), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma that is mismatch repair proficient or not microsatellite instability-high.
Leqembi (lecanemab)
(lecanemab)Eisai Inc.
Usage: LEQEMBI is indicated for treating Alzheimer's disease in patients with mild cognitive impairment or mild dementia, based on clinical trial results.